Baker Brothers portfolio, Q3 2025

Baker Bros. Advisors · 13F for the quarter ending Sep 30, 2025

For Q3 2025, Baker Bros. Advisors reported $13.8B across 91 US-listed positions, led by ONC (21.7%), INCY (18.8%) and MDGL (7.1%). Compared with its filing for Q2 2025, Baker Brothers opened 12 new positions, added to 14, reduced 5 and sold out of 10; 60 positions did not change.

The largest purchase was an addition to CELC ($121.8M); the largest sale, a reduction of INSM ($145.4M).

Reported value
$13.8B
Positions
91
In the top 10
79%
Filed
Nov 14
2025

Key facts

13F portfolio value
$13.8BQ3 2025
Positions
91
Largest holding
ONC 21.7%
New positions
12
Sold out
10
Filed
Nov 14, 2025

Holdings as of (Q3 2025), filed with the SEC on . Changes are measured against the filing for Jun 30, 2025. Every tracked investor's Q3 2025 13F.

Bought and sold in Q3 2025

Baker Brothers: buys and sells in Q3 2025
StockMoveSharesSizeOf portfolio
Insmed IncINSM▼ Reduced 13%−1.01M$145.4M1.05%
Celcuity IncCELC▲ Added 45%+2.47M$121.8M0.88%
Madrigal Pharmaceuticals IncMDGL▲ Added 8.4%+165.68K$76M0.55%
Abivax SAABVX▲ New+875.8K$74.4M0.54%
Alkermes PLCALKS▲ Added 26%+1.68M$50.4M0.36%
Celcuity Incno ticker on file
▲ New—$40.9M0.30%
Ionis Pharmaceuticals IncIONS▲ New+566.8K$37.1M0.27%
IDEAYA Biosciences IncIDYA▲ Added 55%+1.16M$31.5M0.23%
Rapport Therapeutics IncRAPP▲ Added 181%+997K$29.6M0.21%
Avidity Biosciences Incno ticker on file
▲ New+625K$27.2M0.20%
Structure Therapeutics IncGPCR▼ Reduced 38%−952.66K$26.7M0.19%
Arrowhead PharmaceuticalsARWR▲ Added 78%+731.59K$25.2M0.18%
Verona Pharma Plcno ticker on file
▼ Sold out−223.84K$21.2M0.15%
Verve Therapeutics Incno ticker on file
▼ Sold out−1.69M$19M0.14%
Immatics N.V.IMTX▲ Added 19%+1.93M$16.4M0.12%
Blueprint Medicines Corpno ticker on file
▼ Sold out−125.54K$16.1M0.12%
Viking Therapeutics IncVKTX▲ New+366.08K$9.6M0.07%
Pharvaris N VPHVS▲ New+375K$9.4M0.07%
Spyre Therapeutics IncSYRE▲ Added 60%+373.3K$6.3M0.05%
Heron Therapeutics IncHRTX▲ New+4.25M$5.4M0.04%
Xencor IncXNCR▲ Added 64%+431.68K$5.1M0.04%
MBX Biosciences IncMBX▲ New+277.78K$4.9M0.04%
IGM Biosciences Incno ticker on file
▼ Sold out−4.1M$4.6M0.03%
Cerus CorpCERS▼ Reduced 22%−2.88M$4.6M0.03%
Revolution Medicines IncRVMD▲ Added 1.0%+90.39K$4.2M0.03%
Ventyx Biosciences Incno ticker on file
▲ New+1.02M$3.2M0.02%
LB Pharmaceuticals IncLBRX▲ New+200K$3.2M0.02%
Fate Therapeutics IncFATE▼ Sold out−2.49M$2.8M0.02%
Contineum Therapeutics IncCTNM▼ Reduced 75%−234.83K$2.8M0.02%
CytomX Therapeutics IncCTMX▲ Added 22%+766.6K$2.4M0.02%
Candel Therapeutics IncCADL▼ Sold out−355.11K$1.8M0.01%
Rocket Pharmaceuticals IncRCKT▼ Sold out−552.08K$1.4M0.01%
Intellia Therapeutics IncNTLA▲ Added 2.7%+71K$1.2M0.01%
vTv Therapeutics IncVTVT▲ Added 52%+51K$1.2M0.01%
Generation Bio Cono ticker on file
▲ New+194.49K$1.2M0.01%
HOOKIPA Pharma Incno ticker on file
▼ Sold out−812.81K$1M0.01%
Neumora Therapeutics IncNMRA▼ Sold out−1.03M$758.7K0.01%
Generation Bio Cono ticker on file
▼ Sold out−1.94M$622.6K0.00%
KALA BIO IncKALA▼ Reduced 18%−216.8K$331.7K0.00%
VYNE Therapeutics Incno ticker on file
▲ New+851.35K$285.2K0.00%
Incyte CorpINCY▲ Added 0.00%+388$32.9K0.00%

Holdings at the quarter's end

Baker Brothers holdings, Q3 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q2 2025
1Beone Medicines LtdONC · SPONSORED ADSHealth Care21.7%$3B8.8M$340.706+ qtrsNo change
2Incyte CorpINCYHealth Care18.8%$2.6B30.74M$84.816+ qtrs▲ Added 0.00%
3Madrigal Pharmaceuticals IncMDGLHealth Care7.10%$982.3M2.14M$458.666+ qtrs▲ Added 8.4%
4Insmed IncINSMHealth Care6.98%$965.4M6.7M$144.016+ qtrs▼ Reduced 13%
5Acadia Pharmaceuticals IncACAD—6.62%$915.4M42.9M$21.346+ qtrsNo change
6Summit Therapeutics IncSMMTHealth Care5.04%$696.7M33.72M$20.666+ qtrsNo change
7Rhythm Pharmaceuticals IncRYTMHealth Care4.09%$566M5.6M$100.996+ qtrsNo change
8Revolution Medicines IncRVMDHealth Care3.19%$441.6M9.46M$46.706+ qtrs▲ Added 1.0%
9Celcuity IncCELC—2.83%$391M7.92M$49.406+ qtrs▲ Added 45%
10Kymera Therapeutics IncKYMRHealth Care2.72%$376.5M6.65M$56.606+ qtrsNo change
11Kodiak Sciences IncKODHealth Care2.05%$283.4M17.31M$16.376+ qtrsNo change
12Alkermes PLCALKS · SHSHealth Care1.75%$242.7M8.09M$30.006+ qtrs▲ Added 26%
13Abcellera Biologics IncABCL—1.00%$138.5M27.53M$5.036+ qtrsNo change
14Edgewise Therapeutics IncEWTXHealth Care0.86%$118.5M7.31M$16.226+ qtrsNo change
15Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.79%$109.7M2.82M$38.836+ qtrsNo change
16Stoke Therapeutics IncSTOK—0.79%$108.9M4.63M$23.506+ qtrsNo change
17Immatics N.V.IMTX · SHS—0.75%$103M12.09M$8.526+ qtrs▲ Added 19%
18Grail IncGRALHealth Care0.70%$96.4M1.63M$59.134 qtrsNo change
19IDEAYA Biosciences IncIDYA—0.64%$89.1M3.28M$27.216+ qtrs▲ Added 55%
20Immunovant IncIMVTHealth Care0.64%$88M5.46M$16.126+ qtrsNo change
21Immunocore Holdings plcIMCR · ADS—0.61%$84.4M2.32M$36.336+ qtrsNo change
22Bicycle Therapeutics PlcBCYC · SPONSORED ADS—0.61%$84.3M10.89M$7.746+ qtrsNo change
23Ultragenyx PharmaceuticalRARE—0.60%$83.4M2.77M$30.086+ qtrsNo change
24Abivax SAABVX · SPONSORED ADSHealth Care0.54%$74.4M875.8K$84.901 qtrNew
25Arrowhead PharmaceuticalsARWRHealth Care0.42%$57.6M1.67M$34.492 qtrs▲ Added 78%
26Roivant Sciences LtdROIV · SHSHealth Care0.41%$57M3.77M$15.136+ qtrsNo change
27Denali Therapeutics IncDNLI—0.39%$54.2M3.73M$14.526+ qtrsNo change
28
Merus N Vno ticker on file
—0.39%$54.1M574.38K$94.156+ qtrsNo change
29Intellia Therapeutics IncNTLA—0.34%$47.4M2.75M$17.274 qtrs▲ Added 2.7%
30Replimune Group IncREPL—0.33%$46.3M11.05M$4.196+ qtrsNo change
31Rapport Therapeutics IncRAPP—0.33%$45.9M1.55M$29.702 qtrs▲ Added 181%
32Structure Therapeutics IncGPCR · SPONSORED ADS—0.32%$43.6M1.56M$28.005 qtrs▼ Reduced 38%
33
Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031
—0.30%$40.9M——1 qtrNew
34Viridian Therapeutics IncVRDN—0.27%$37.6M1.74M$21.582 qtrsNo change
35Ionis Pharmaceuticals IncIONSHealth Care0.27%$37.1M566.8K$65.421 qtrNew
36Praxis Precision MedicinesPRAXHealth Care0.26%$36.5M689.49K$53.006+ qtrsNo change
37Monte Rosa Therapeutics IncGLUE—0.26%$36.4M4.92M$7.416+ qtrsNo change
38BioNTech SEBNTX · SPONSORED ADSHealth Care0.26%$36.4M368.92K$98.624 qtrsNo change
39Nurix Therapeutics IncNRIX—0.26%$35.9M3.88M$9.246+ qtrsNo change
40Dianthus Therapeutics IncDNTHHealth Care0.23%$31.1M789.76K$39.352 qtrsNo change
41Entrada Therapeutics IncTRDA—0.20%$28.2M4.87M$5.806+ qtrsNo change
42argenx SEARGX · SPONSORED ADRHealth Care0.20%$27.9M37.76K$737.566+ qtrsNo change
43
Avidity Biosciences Incno ticker on file
—0.20%$27.2M625K$43.571 qtrNew
44Vaxcyte IncPCVXHealth Care0.17%$23.1M640.89K$36.026+ qtrsNo change
45Disc Medicine IncIRON—0.16%$22.3M337.05K$66.084 qtrsNo change
46
Cidara Therapeutics Incno ticker on file
—0.16%$21.8M227.27K$95.762 qtrsNo change
47Celldex Therapeutics IncCLDX—0.12%$17.2M665.37K$25.876+ qtrsNo change
48Neurogene IncNGNE—0.12%$17.2M991.69K$17.336+ qtrsNo change
49Sera Prognostics IncSERA · CLASS A COM—0.12%$16.8M5.5M$3.066+ qtrsNo change
50Spyre Therapeutics IncSYREHealth Care0.12%$16.8M1M$16.762 qtrs▲ Added 60%
51Cerus CorpCERS—0.12%$15.9M10.01M$1.596+ qtrs▼ Reduced 22%
52
Akero Therapeutics Incno ticker on file
—0.11%$15.4M324.63K$47.486+ qtrsNo change
53Xenon Pharmaceuticals IncXENE—0.11%$14.9M370.21K$40.156+ qtrsNo change
54Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.11%$14.6M1.46M$10.006+ qtrsNo change
55Prelude Therapeutics IncPRLD—0.11%$14.6M10.12M$1.446+ qtrsNo change
56
Arcellx Incno ticker on file
—0.10%$13.7M166.83K$82.102 qtrsNo change
57CytomX Therapeutics IncCTMX—0.10%$13.6M4.25M$3.192 qtrs▲ Added 22%
58Taysha Gene Therapies IncTSHA—0.10%$13.1M4M$3.276+ qtrsNo change
59Xencor IncXNCR—0.09%$12.9M1.1M$11.736+ qtrs▲ Added 64%
60Design Therapeutics IncDSGN—0.09%$12.9M1.71M$7.536+ qtrsNo change
61
Nuvalent Incno ticker on file
—0.09%$12.4M143.94K$86.482 qtrsNo change
62Sionna Therapeutics IncSION—0.09%$11.8M400K$29.413 qtrsNo change
63
Crinetics Pharmaceuticalsno ticker on file
—0.08%$11.7M280K$41.652 qtrsNo change
64Viking Therapeutics IncVKTX—0.07%$9.6M366.08K$26.281 qtrNew
65Pharvaris N VPHVS—0.07%$9.4M375K$24.951 qtrNew
66Agios Pharmaceuticals IncAGIO—0.06%$7.6M189.87K$40.142 qtrsNo change
67Sana Biotechnology IncSANA—0.05%$7.2M2.03M$3.556+ qtrsNo change
68Sagimet Biosciences IncSGMT—0.05%$6.5M953K$6.866+ qtrsNo change
69Alumis IncALMS—0.05%$6.2M1.56M$3.996+ qtrsNo change
70Relay Therapeutics IncRLAY—0.04%$6.1M1.16M$5.226+ qtrsNo change
71Skye Bioscience IncSKYE—0.04%$5.7M1.45M$3.936+ qtrsNo change
72Heron Therapeutics IncHRTX—0.04%$5.4M4.25M$1.261 qtrNew
73TScan Therapeutics IncTCRX—0.04%$5.1M2.78M$1.826+ qtrsNo change
74MBX Biosciences IncMBX—0.04%$4.9M277.78K$17.501 qtrNew
75vTv Therapeutics IncVTVT · CL A—0.03%$3.5M148.31K$23.356+ qtrs▲ Added 52%
76
Ventyx Biosciences Incno ticker on file
—0.02%$3.2M1.02M$3.111 qtrNew
77LB Pharmaceuticals IncLBRX—0.02%$3.2M200K$15.791 qtrNew
78Vir Biotechnology IncVIR—0.02%$3.1M542.54K$5.714 qtrsNo change
79Wave Life Sciences LtdWVE · SHS—0.02%$2.5M344.06K$7.325 qtrsNo change
80Enliven Therapeutics IncELVN—0.02%$2.4M114.83K$20.476+ qtrsNo change
81Protara Therapeutics IncTARA—0.02%$2.3M536.83K$4.356+ qtrsNo change
82Tectonic Therapeutic IncTECX—0.01%$1.6M100K$15.693 qtrsNo change
83KALA BIO IncKALA—0.01%$1.5M985.09K$1.536+ qtrs▼ Reduced 18%
84
Generation Bio Cono ticker on file
—0.01%$1.2M194.49K$6.121 qtrNew
85Contineum Therapeutics IncCTNM · CL A—0.01%$912.6K77.67K$11.756+ qtrs▼ Reduced 75%
86Aligos Therapeutics IncALGS—0.01%$813.9K83.06K$9.806+ qtrsNo change
87
VYNE Therapeutics Incno ticker on file
—0.00%$285.2K851.35K$0.33501 qtrNew
88Tyra Biosciences IncTYRA—0.00%$148.4K10.61K$13.996+ qtrsNo change
89Acrivon Therapeutics IncACRV—0.00%$41.3K22.81K$1.816+ qtrsNo change
90
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$14.8K833.33K$0.01786+ qtrsNo change
91
Opthea Limitedno ticker on file · SPONSORED ADS
—0.00%$02.09M—6+ qtrsNo change

By sector

Baker Brothers portfolio by sector, Q3 2025
SectorShare of portfolioValuePositions
Health Care79.3%$11B24
No sector on file20.7%$2.9B67

Questions and answers

What did Baker Brothers own in Q3 2025?

Baker Bros. Advisors's 13F for Q3 2025 lists 91 positions worth $13.8B. The largest: ONC (21.7%), INCY (18.8%), MDGL (7.1%), INSM (7.0%), ACAD (6.6%).

What did Baker Brothers buy in Q3 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: CELC (added, $121.8M), MDGL (added, $76M), ABVX (new, $74.4M), ALKS (added, $50.4M), Celcuity Inc (new, $40.9M), IONS (new, $37.1M).

What did Baker Brothers sell in Q3 2025?

The largest sales: INSM (reduced, $145.4M), GPCR (reduced, $26.7M), Verona Pharma Plc (sold out, $21.2M), Verve Therapeutics Inc (sold out, $19M), Blueprint Medicines Corp (sold out, $16.1M), IGM Biosciences Inc (sold out, $4.6M).

When was this filing made?

Baker Bros. Advisors filed its 13F for the quarter ending Sep 30, 2025 on Nov 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio, Q3 2025: Baker Bros. Advisors 13F holdings”, data as of 14 November 2025. https://funkfolio.com/gurus/baker-brothers/2025-q3

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Sep 30, 2025.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Sep 30, 2025, filed Nov 14, 2025. Changes compare share counts with the filing for Jun 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $13.8B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 6 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.